Struggling CellRev, Britain's cultured meat technology company, halts operations due to financial difficulties.
UK Biotech Firm CellulaREvolution (CellRev) Enters Administration
In a significant turn of events, UK-based biotech company CellulaREvolution (CellRev) has entered administration. The company, which specializes in cell culture technologies, has been a key player in the cultivated meat, regenerative medicine, and vaccine sectors.
The joint administrators, Ed Connell and Mike Kienlen from advisory firm Armstrong Watson, were appointed on August 12. They are currently working with Hilco Valuation Services to realize the assets of the company. Unfortunately, this move has resulted in all staff members being made redundant.
CellRev's pivot away from the cultivated meat sector and its focus on the life sciences opportunity, specifically vaccines, came after a series of challenges. The company's CEO, Chris Green, stated that they couldn't deliver commercial milestones fast enough to secure Series A investment.
Despite these challenges, CellRev settled on vaccines as its target and secured commercial partnerships. They began conducting pilots and even signed deals to develop a cell and gene therapy product range. The company's flagship product, AggreGuard, a specialist enzyme blend that prevents cells from clumping together during production, has been a key component of these efforts.
In a notable milestone, CellRev secured its first pharma evaluation. However, the company's fortunes in the cultivated meat sector have been less favourable. The sector has faced significant fundraising difficulties, with cumulative funding decreasing dramatically over the past two years. In 2024, cultivated meat witnessed a 40% decline in funding, securing only $139M, its lowest annual total since 2019.
FlyBlast, another company targeting the cultivated meat sector, declared bankruptcy and blamed its strategy for the sector as a contributing factor. SciFi Foods also wound down after facing similar fundraising issues.
In a bid to mass-produce cultivated meat in a cost-effective manner, CellRev partnered with BSF Enterprise in December 2023. However, BSF abandoned the joint venture late last year. This year has been even bleaker for the cultivated meat sector, with companies in this space receiving just $35M in the first six months.
CellRev also offers And Continuase, a continuous cell manufacturing enzyme solution. Despite these innovations, the company's financial struggles have led to its current situation. The company that specialized in therapeutic production in 2024 after selling its cultivated meat assets is not explicitly named in the available results, and the buyer of the cultivated meat assets is also not mentioned in the provided search results.
As the administration process continues, the future of CellRev and its groundbreaking cell culture technologies remains uncertain. The biotech industry will be closely watching the developments surrounding this once-promising company.
Read also:
- visionary women of WearCheck spearheading technological advancements and catalyzing transformations
- A continuous command instructing an entity to halts all actions, repeated numerous times.
- Oxidative Stress in Sperm Abnormalities: Impact of Reactive Oxygen Species (ROS) on Sperm Harm
- Is it possible to receive the hepatitis B vaccine more than once?
